UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS
Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
| (Former Name or Former Address, if Changed Since Last Report) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name on exchange on which registered | ||
| The
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2 of the Securities Act of 1934: Emerging growth company
If any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Information
On February 4, 2021, Surface Ophthalmics, Inc. (“Surface”) issued a press release (the “Surface PR”) announcing the first patient dosed in a phase II trial for its drug candidate SURF-200 (betamethasone in Klarity vehicle) for the treatment of acute dry eye. According to the Surface PR, in the dose ranging study SURF-200 will be administered in two different low concentration formulations of betamethasone in the Klarity vehicle. The trial will enroll 120-140 patients with a primary endpoint of Symptom Improvement of one unit based on the University of North Carolina Dry Eye Management Scale by the eighth day.
Harrow Health, Inc. owns three million five hundred thousand (3,500,000) shares of Surface common stock, which is approximately 30% of the issued and outstanding voting interests of Surface, along with a mid-single digit royalty right on net sales of SURF-200.
The foregoing is only a brief description of the Surface PR, does not purport to be a complete description of the Surface PR and is qualified in its entirety by reference to the full text of the document, which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
All trademarks referenced in this Current Report on Form 8-K and the Surface PR are the property of their respective owners.
Item 9.01. Financial Statements and Exhibits
| (d) | Exhibits |
| Item | Description | |
| 99.1 | Surface Ophthalmics Press Release Date February 4, 2021 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HARROW HEALTH, INC. | ||
| Dated: February 4, 2021 | By: | /s/ Andrew R. Boll |
| Name: | Andrew R. Boll | |
| Title: | Chief Financial Officer | |
EXHIBIT 99.1
Surface Ophthalmics Announces First Patient Dosed in Phase II Trial for SURF-200 for Acute Dry Eye
SURF-200 leverages the proven Klarity vehicle and betamethasone corticosteroid to treat acute dry eye
PLEASANTON, California 4 FEBRUARY 2021 – Surface Ophthalmics, Inc., a pharmaceutical company focused on the development and commercialization of innovative therapeutics for ocular diseases, today announced that the first patient has been dosed in the Phase II clinical trial for its investigational product SURF-200 (betamethasone in Klarity vehicle) for the treatment of acute dry eye.
In this dose-ranging study, SURF-200 will be studied in two different low concentration formulations, which include betamethasone, a corticosteroid with a strong track record in global use but is now making its debut in the ocular space in the United States, in the Klarity vehicle. SURF-200 has been formulated to provide comparable efficacy with an improved safety and tolerability profile when compared to currently used steroids. The trial will enroll between 120-140 patients with a primary endpoint of Symptom Improvement of one unit based on the University of North Carolina Dry Eye Management Scale by the eighth day.
Kamran Hosseini, MD, PhD, President and CEO, Surface Ophthalmics, said “We’re excited to have our first patient dosed for our SURF-200 Phase II clinical trial. Following last week’s initiation of the bold SURF-100 head-to-head clinical trial in chronic dry eye disease, we’re proud to be enrolling patients in clinical trials for both acute dry eye and chronic dry eye disease. We are the only company committed to working to meet all of the needs of dry eye patients.”
“With limited treatment options for acute dry eye, we have a great need for an effective and well-tolerated therapeutic for patients suffering from periods of acute dry eye,” stated Preeya Gupta, MD, Associate Professor of Ophthalmology at Duke University Eye Center, lead investigator for the SURF-200 clinical trial. “With a proven diluent designed to protect the ocular surface and a potent corticosteroid, I’m hopeful that SURF-200 will provide a much-needed treatment option.”
“At Surface Ophthalmics, we are off to a great start in 2021! We began the year with positive topline Phase II data from SURF-201 for pain and inflammation following ocular surgery,” said Hosseini. “Then we initiated two additional Phase II trials - first a head-to-head trial for SURF-100 against Restasis® and Xiidra® and now SURF-200 for acute dry eye. We’re focusing on strong clinical progress this year and look forward to sharing more information as it becomes available.”
ABOUT OUR CLINICAL PROGRAMS
Surface Ophthalmics is advancing three clinical programs: one in chronic dry eye disease (SURF-100), one in acute dry eye (SURF-200), and one in pain and inflammation following ocular surgery (SURF-201). These programs utilize Klarity as the delivery vehicle, which is designed to enhance patient comfort as well as protect and rehabilitate the ocular surface.
In only two years, Surface has filed three unique INDs and officially moved all three of the programs into Phase II trials.
ABOUT KLARITY
The patented Klarity delivery vehicle is used across Surface Ophthalmic’s three current clinical programs. Developed by Richard L. Lindstrom, MD, inventor of Optisol GS (an advanced corneal preservation solution), Klarity is designed to enhance patient comfort as well as protect and rehabilitate the ocular surface pathology for patients with moderate-to-severe dry eye disease.
ABOUT SURFACE OPHTHALMICS
Surface Ophthalmics, Inc. is a pharmaceutical company focused on the development and commercialization of innovative therapeutics for ocular diseases. We are striving to solve key patient needs in eye care through leveraging deep expertise, a bold approach, an eye toward efficiency, and a clear, differentiated clinical advantages. Our current drug pipeline consists of three proprietary drug candidates, all utilizing Klarity®, a patented delivery vehicle. We are led by an experienced and proven management team and board of directors with over 80 years of ophthalmology related professional experience. For more information: http://www.surfaceophthalmics.com.
CONTACTS
Media Inquiries
Lindsey Reichelt
lindsey@reicheltcommunications.com
Cover |
Feb. 04, 2021 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Feb. 04, 2021 |
| Entity File Number | 001-35814 |
| Entity Registrant Name | HARROW HEALTH, INC. |
| Entity Central Index Key | 0001360214 |
| Entity Tax Identification Number | 45-0567010 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 102 Woodmont Blvd. |
| Entity Address, Address Line Two | Suite 610 |
| Entity Address, City or Town | Nashville |
| Entity Address, State or Province | TN |
| Entity Address, Postal Zip Code | 37205 |
| City Area Code | (615) |
| Local Phone Number | 733-4730 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, $0.001 par value per share |
| Trading Symbol | HROW |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Entity Information, Former Legal or Registered Name | Not Applicable |
-8?20$3;8T.P6BP^0"X9
M9K>]9!:G